Cambria 1: Camizestrant Er+/Her2- Early Breast Cancer

CAMBRIA 1: camizestrant ER+/HER2- early breast cancer

CAMBRIA-1: camizestrant vs standard endocrine therapy in breast cancer

First-line camizestrant for ER+/HER2- advanced breast cancer

Mafalda Oliveira, SABCS 2022: Camizestrant vs fulvestrant for advanced ER+ HER2- breast cancer

Touch Medical Media Services

Camizestrant may be superior to fulvestrant in patients with HR-positive, HER2-negative BC

How to use endocrine therapy in premenopausal women with ER+ early breast cancer

European Society for Medical Oncology (ESMO)

SERENA-2: camizestrant vs fulvestrant in post-menopausal women with advanced ER+/HER- breast cancer

EMBER-2: preoperative imlunestrant for ER+/HER2- early stage breast cancer

The CAMBRIA-2 Clinical Trial

Breast Cancer Trials

Diagnosis of HER2+/ER- Early Breast Cancer

Targeted Oncology

PREcoopERA: giredestrant versus anastrozole in ER+/HER2- early breast cancer

Case 1: Approach to Early Stage, HER2+ Breast Cancer

Targeted Oncology

Treatment for Early-Stage ER+ Breast Cancer

HER2+ Early-Stage Breast Cancer: Peri-Operative Therapy

Case 1: Early-Stage HER2+ Breast Cancer

Targeted Oncology

New Breast Cancer Clinical Trial: Imlunestrant for Breast Cancer

Power Life Sciences

Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast cancer: ELAINE trial

Early Stage Breast Cancer | 2022 OneOncology Conference

Total Health | Oncology

EMERALD: elacestrant vs physicians choice in ER+/HER2- breast cancer